Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CalciMedica (CALC) just unveiled an announcement.
CalciMedica, Inc. announced positive results from its Phase 2b CARPO trial of Auxora for treating acute pancreatitis with systemic inflammatory response syndrome. The study met its objectives, showing a significant dose-response in reducing the time to solid food tolerance and severe organ failure. High and medium doses of Auxora led to a considerable decrease in hospital stay and risk of prolonged hospitalization, with a good safety profile indicated by the number of treatment-emergent serious adverse events. The company plans to present further data later this year and is moving forward with additional trials for Auxora in different medical conditions.
Find detailed analytics on CALC stock on TipRanks’ Stock Analysis page.